Adipotide
Prohibitin-targeting FTPP — monkey/mouse only; refuse human fat-loss glow.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. Adipotide is a prohibitin-targeting peptidomimetic designed to home to adipose vasculature and induce endothelial apoptosis (often abbreviated in literature as a CKGGRAKDC–GG–D(KLAKLAK)2-class construct / FTPP framing). PubChem CID 163360068; formula C111H206N36O28S2 / MW 2557.2; CAS 859216-15-2. Human clinical efficacy trials are absent from this pack. Preclinical mouse and obese-monkey weight-loss papers are not human grades. No approved indication. Off-label does not apply. There is no label to be off of. Refuse human fat-loss glow. This drawer marks papers. It is not use advice.
Bottom line
The PubMed core is Kolonin/Barnhart-line targeted adipose ablation work in rodents and obese monkeys, plus secondary obesity-nanomedicine commentary. No controlled human outcome trials for Adipotide appear in this Selected sources set. Refuse fat-loss glow from monkey weight loss.
Papers
Foundational / preclinical efficacy objects
PMID 15133506 — Kolonin 2004
Tested: targeted ablation of adipose tissue reversing obesity in mice using a prohibitin-binding peptide motif fused to a proapoptotic sequence.
Does not show: a human obesity RCT or long-term safety in people.
PMID 22072637 — Barnhart 2011
Tested: peptidomimetic targeting white fat causing weight loss and improved insulin resistance in obese monkeys.
Does not show: human efficacy, approved indication, or that gray-market vials match published material.
PMID 22733798 — Kim 2012
Tested: rapid, weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium (preclinical metabolic framing).
Does not show: a human diabetes indication.
Commentary / secondary (not primary efficacy grades)
PMID 22539771 — Criscione 2012
Tested: comment on the Barnhart obese-monkey peptidomimetic paper.
Does not show: new primary efficacy data.
PMID 23871959 — Hossen 2013
Tested: comparative review framing nanoparticle-targeted therapeutics vs bioconjugates as obesity medication concepts (includes targeted adipose strategies).
Does not show: human Adipotide approval.
What is not established
Any human clinical efficacy or approved fat-loss indication for Adipotide. Safety of endothelial-targeted apoptotic peptides in people. Equivalence of unlabeled research chemicals to published FTPP constructs. That monkey weight loss equals consumer outcomes. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.